Zura Bio (NASDAQ:ZURA) Research Coverage Started at Cantor Fitzgerald

Cantor Fitzgerald started coverage on shares of Zura Bio (NASDAQ:ZURA) in a report published on Wednesday, Marketbeat.com reports. The firm issued an overweight rating on the stock. Cantor Fitzgerald also issued estimates for Zura Bio’s FY2024 earnings at ($0.64) EPS.

ZURA has been the topic of a number of other reports. Oppenheimer boosted their price objective on Zura Bio from $16.00 to $21.00 and gave the company an outperform rating in a research note on Friday, May 10th. Piper Sandler initiated coverage on shares of Zura Bio in a research report on Friday, May 3rd. They issued an overweight rating and a $26.00 price objective for the company. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Zura Bio presently has a consensus rating of Buy and an average price target of $19.80.

Zura Bio Price Performance

Shares of NASDAQ ZURA opened at $3.77 on Wednesday. The stock has a fifty day simple moving average of $4.34 and a two-hundred day simple moving average of $3.98. Zura Bio has a 1-year low of $2.00 and a 1-year high of $13.00.

Zura Bio (NASDAQ:ZURA) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.21. Equities research analysts expect that Zura Bio will post -0.53 earnings per share for the current fiscal year.

Insider Activity at Zura Bio

In related news, Director Amit Munshi acquired 159,744 shares of the company’s stock in a transaction dated Monday, April 22nd. The stock was bought at an average cost of $3.13 per share, with a total value of $499,998.72. Following the acquisition, the director now owns 777,384 shares of the company’s stock, valued at approximately $2,433,211.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Zura Bio news, Director Van Amstel Arnout Ploos purchased 80,000 shares of the firm’s stock in a transaction on Friday, May 17th. The shares were purchased at an average cost of $6.20 per share, with a total value of $496,000.00. Following the completion of the purchase, the director now owns 100,000 shares of the company’s stock, valued at approximately $620,000. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Amit Munshi bought 159,744 shares of Zura Bio stock in a transaction that occurred on Monday, April 22nd. The shares were acquired at an average cost of $3.13 per share, for a total transaction of $499,998.72. Following the acquisition, the director now owns 777,384 shares in the company, valued at approximately $2,433,211.92. The disclosure for this purchase can be found here. Insiders have purchased 250,926 shares of company stock valued at $1,030,998 over the last three months. 15.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Zura Bio

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Armistice Capital LLC grew its holdings in Zura Bio by 15.4% in the 4th quarter. Armistice Capital LLC now owns 1,824,000 shares of the company’s stock worth $8,518,000 after acquiring an additional 244,000 shares during the last quarter. Affinity Asset Advisors LLC purchased a new position in Zura Bio during the 1st quarter valued at about $1,157,000. Silverarc Capital Management LLC raised its position in Zura Bio by 152.5% during the 3rd quarter. Silverarc Capital Management LLC now owns 404,040 shares of the company’s stock valued at $2,667,000 after purchasing an additional 244,040 shares during the last quarter. Eisler Capital US LLC purchased a new stake in Zura Bio in the 3rd quarter worth approximately $660,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of Zura Bio in the 3rd quarter worth approximately $224,000. 61.14% of the stock is currently owned by institutional investors.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.